. Ipsilateral adrenalectomy at the time of radical nephrectomy, as described by Robson et al., 12 should likely be limited to those with suspicious findings on imaging or those with suspicious operative findings, unless surgically unavoidable. Furthermore
Robert Torrey, Philippe E. Spiess, Sumanta K. Pal and David Josephson
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld and Jue Wang
Hollingsworth JM Miller DC Dunn RL . Surgical management of low-stage renal cell carcinoma: technology does not supersede biology . Urology 2006 ; 67 : 1175 – 1180 . 10 Shuch B Lam JS Belldegrun AS . Open partial nephrectomy for the treatment or
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang and Richard B. Wilder
with stage I, 82% for stage II, 64% for stage III, and 23% for stage IV disease. 4 Treatment of Localized Disease Surgical resection remains an effective therapy for clinically localized RCC, with options including radical nephrectomy and
Eric Jonasch
appropriate situation (such as for a patient with a good performance status and a readily resectable primary tumor) with cytoreductive nephrectomy [ Figure 1 ] and then systemic therapy [ Figure 2 ],” stated Dr. Jonasch. In the 2015 NCCN Guidelines for
David Y. T. Chen and Robert G. Uzzo
Edited by Kerrin G. Robinson
: casting doubt on the efficacy of early intervention . Urology 2001 ; 57 : 1013 – 1015 . 3 Hollenbeck BK Taub DA Miller DC . National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology
Rodger J. Winn
References 1 McKiernan JM Teschendorf B Katz J . A comparison of hospital-based charges following partial and radical nephrectomy . Urol Oncol 2002 ; 7 : 3 - 6 . 2 Uzzo RG Wei JT Hafez . Comparison of direct hospital
Michael P. Porter and Paul H. Lange
Statistics Review, 1975-2001. Bethesda, MD : National Cancer Institute ; 2004 . 2 Patard JJ Shvarts O Lam JS . Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience . J Urol 2004 ; 171
Toni K. Choueiri
acts on the disease biology and slows the progression of disease, Dr. Choueiri said. Cytoreduction Nephrectomy in the Targeted Therapy Era The need to obtain tumor tissue in the era of targeted therapies renders biopsy and/or cytoreductive
Saby George, Roberto Pili, Michael A. Carducci and Jenny J. Kim
patients had intermediate Memorial Sloan-Kettering Cancer Center (MSKCC) risk factors (94%) or an intermediate or good University of California, Los Angeles (UCLA) Survival After Nephrectomy and Immunotherapy (SANI) score, and 99% underwent prior
Ralph Hauke
Vasey P Aitchison M . Management of renal masses in patients medically unsuitable for nephrectomy— natural history, complications, and outcome . Urology 2004 ; 64 : 909 – 913 . 33. Ozono S Miyao N Igarashi T . Tumour doubling time of
